CONNECT WITH US
HealthTech

HealthTech

Abbott’s defibrillation lead lands FDA approval and CE mark

MedTech Dive logo

Published on

Add as a preferred source on Google
Abbott’s defibrillation lead lands FDA approval and CE mark

The authorizations position Abbott to launch a purpose-built lead for left bundle branch area pacing in the U.S. and Europe.

Abbott designed UltiSynq by modifying its Optisure implantable cardioverter defibrillator lead for use in the left bundle branch area. Developers of medical devices for cardiac resynchronization therapy with a defibrillator have incorporated LBBA pacing amid evidence of its benefits over right ventricular pacing. However, the incorporation has necessitated an additional pacing lead within the LBBA.

UltiSynq, a purpose-built ICD lead for conduction system pacing, is designed for implantation within the LBBA. The device is designed for long-term attachment to compatible ICD or CRT-D systems in patients at risk of sudden cardiac death due to life-threatening tachyarrhythmias. Abbott validated the device in ASCEND CSP, a pivotal trial that enrolled patients undergoing ICD or CRT-D implantation.

Physicians implanted the UltiSynq lead successfully in 202 of 205 patients. The lead stimulated, or likely stimulated, the heart’s natural conduction pathway in 86% of patients. The other 14% had left ventricular septal pacing. Successful defibrillation was seen in all of the 120 patients who completed defibrillation testing. After three months, 97.5% of patients were free from major complications.

“The observed implant success, LBBAP capture results and defibrillation testing outcomes give physicians compelling data on this lead option for patients who require defibrillation protection and are candidates for conduction system pacing,” Pugazhendhi Vijayaraman, system director of cardiac electrophysiology at Geisinger Heart Institute, said in a statement.

S. and European markets. S. and Europe implant about 150,000 and 140,000 ICDs, respectively, each year.


Source link
Related Topics:HealthTech

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.